Loading patent…
AssigneeNorth Carolina State University
InventorsKe Cheng, Dashuai Zhu
Estimating the term…
Provided are compositions and methods useful in regenerating damaged tissue, especially cardiac tissue, by delivering to the site of injury an miRNA that can reduce, for example, the expression of phosphatase and tensin homolog (PTEN). The compositions and methods of the disclosure may be generally applied to deliver an miRNA to a cell or tissue such as, but not limited to, a neuron, a smooth muscle cell, or a tumor cell. The compositions comprise a transmembrane carrier peptide conjugated, optionally by a linker, to an oligonucleotide complementary to an miRNA. The carrier peptide facilitates the entry of the miRNA into cells and for delivery to a tissue of an animal or human may be mixed with an extracellular matrix-derived hydrogel carrier.
A composition comprising a passenger chain oligonucleotide connected to a cell-penetrating peptide.
A method of delivering an miRNA to a cell, the method comprising contacting a cell with a composition comprising a passenger chain oligonucleotide connected to a cell-penetrating peptide, wherein the cell-penetrating peptide and the passenger chain oligonucleotide are connected by a linker covalently conjugated to the cell-penetrating peptide and to the passenger chain oligonucleotide, and wherein the composition further comprises an miRNA oligonucleotide having a nucleotide sequence selectively hybridized to the passenger chain nucleotide sequence.
A pharmaceutically acceptable carrier generated from decellularized cardiac extracellular matrix.
A therapeutic composition comprising a composition comprising a passenger chain oligonucleotide connected to a cell-penetrating peptide, wherein the cell-penetrating peptide and the passenger chain oligonucleotide are connected by a linker covalently conjugated to the cell-penetrating peptide and to the passenger chain oligonucleotide, and wherein the composition further comprises an miRNA oligonucleotide having a nucleotide sequence selectively hybridized to the passenger chain nucleotide sequence. and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.